Minerva Neurosciences (NASDAQ:NERV) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a report issued on Friday.
Other analysts also recently issued research reports about the stock. Zacks Investment Research raised shares of Minerva Neurosciences from a “hold” rating to a “buy” rating and set a $7.25 price target for the company in a research note on Friday, March 16th. ValuEngine raised shares of Minerva Neurosciences from a “strong sell” rating to a “sell” rating in a research note on Wednesday. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $12.75.
Minerva Neurosciences stock opened at $6.80 on Friday. Minerva Neurosciences has a fifty-two week low of $4.80 and a fifty-two week high of $11.15.
Several institutional investors have recently bought and sold shares of the company. Trexquant Investment LP bought a new position in Minerva Neurosciences in the third quarter worth approximately $189,000. The Manufacturers Life Insurance Company raised its stake in Minerva Neurosciences by 38.8% in the second quarter. The Manufacturers Life Insurance Company now owns 22,359 shares of the biopharmaceutical company’s stock worth $198,000 after buying an additional 6,251 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in Minerva Neurosciences by 47.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 40,835 shares of the biopharmaceutical company’s stock worth $247,000 after buying an additional 13,199 shares in the last quarter. California State Teachers Retirement System raised its stake in Minerva Neurosciences by 7.5% in the second quarter. California State Teachers Retirement System now owns 44,537 shares of the biopharmaceutical company’s stock worth $394,000 after buying an additional 3,100 shares in the last quarter. Finally, Sterling Capital Management LLC raised its stake in Minerva Neurosciences by 25.2% in the third quarter. Sterling Capital Management LLC now owns 52,135 shares of the biopharmaceutical company’s stock worth $396,000 after buying an additional 10,479 shares in the last quarter. 70.13% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This piece of content was first reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3341152/minerva-neurosciences-nerv-stock-rating-upgraded-by-bidaskclub.html.
About Minerva Neurosciences
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.